The Association for the Accreditation of Human Research Protection Programs (AAHRPP) announced that it has awarded five organizations with Full Accreditation. Setting new milestones, in its tenth year, AAHRPP has accredited its first organization in China, first psychiatric hospital, and first federal central IRB. The list also includes two top medical colleges and teaching hospital. Specifically, the following were accredited:
"We are pleased to accredit our first human research protection program at the Beijing YouAn Hospital, Capital Medical University. With China's rapid expansion into clinical trial research we are confident that Beijing YouAn Hospital, Capital Medical University will lead the way for other Chinese institutions to put human safety and wellbeing first by becoming accredited." said Marjorie A. Speers, Ph.D., President and CEO, AAHRPP. Also among first are McLean Hospital and the Veterans Health Administration Central Office Human Research Protections Program, a federal central IRB that reviews multisite studies funded by VA and conducted at local VA facilities. Through the rigorous accreditation process, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to the highest standards for research. The accreditation process typically results in system-wide improvements that enhance protections for research participants and promote high-quality research. Accreditation is available to organizations world-wide that conduct biomedical, behavioral or social sciences research involving human participants.Decisions on accreditation are announced quarterly, and accreditation is valid for three years.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.